Skip main navigation

Home > Search Results

Main contents starts here

Search Results

141 - 160 of about 405

Total 405 documents found.

  •  
  • Consolidated Financial ResultsConsolidated Financial Results First Quarter of Fiscal 2010 Hiroshi Takahara Corporate Officer Senior Vice President Finance & Accounting Department Consolidated Results Summary FY09 Apr-Jun FY10 Apr-Jun billions of yen billions of yen billions of yen Year-on-year change y y y Net Sales 379.0 354.7 - 24.3 - 6.4% Gross Profit 307.6 281.6 - 26.0 - 8.5% SG&A Expenses 117.1 112.2 - 4.9 - 4.2% Excluding Intangible Fixed Assets & Goodw ill Amortization Costs 94.9 94.5 - 0.4 - 0.4% R&D Expenses 64.9 62.1 - 2.8 - 4.2% Operating Income 125.6 107.3 - 18.4 - 14.6% E l di E t di F t 148 0 125 1 22 9 15 5% 2 Excluding Extraordinary Factors 148.0 125.1 - 22.9 - 15.5% Ordinary Income 137.6 103.8 - 33.8 - 24.5% Net Income 112.6 64.1 - 48.5 - 43.1% Excluding Extraordinary Income/Loss & Other Extraordinary Factors 128.1 76.7 - 51.4 - 40.1% E P S * 162.26 yen 97.16 yen - 65.10 yen - 40.1% * Excluding Extraordinary Income/Loss & Other Extraordinary Factors Currency Translation Effect (Comparison wi
  • Summary of Consolidated Financial Results For Fiscal 2009 Forecasts of Consolidated Financial Results For Fiscal 2010 Hiroshi Takahara Corporate Officer Senior Vice President Finance & Accounting Department FY08 FY09 billions of yen billions of yen billions of yen N t S l 1 538 3 1 466 0 72 4 4 7% Year-on-year change FY2009 Consolidated Results Summary Net Sales 1,538.3 1,466.0 - 72.4 - 4.7% Gross Profit 1,248.8 1,180.9 - 67.9 - 5.4% SG&A Expenses 489.3 464.3 - 25.0 - 5.1% Excluding Intangible Fixed Assets & Goodw ill Amortization Costs 405.9 383.9 - 22.1 - 5.4% R&D Expenses 453.0 296.4 - 156.7 - 34.6% Excluding IPR&D Expenses 293.2 296.4 + 3.2 + 1.1% Operating Income 306.5 420.2 + 113.7 + 37.1% Excluding Extraordinary Factors 549.9 500.9 - 49.0 - 8.9%g y 549.9 500.9 49.0 8.9% Ordinary Income 327.2 415.8 + 88.6 + 27.1% Net Income 234.4 297.7 + 63.4 + 27.0% Excluding Extraordinary Income/Loss & Other Extraordinary Factors 380.4 354.3 - 26.1 - 6.9% E P S * 470.30 yen 448.81 yen - 21.49 yen - 4.6% R O E 10.9% 1
  • 16 Special Feature_1 Streamlined Governance for Global Operations Takeda initiated a reorganization of its corporate structure for its worldwide operations beginning April 2009. This initiative is focused on empowering the company to more flexibly respond to the rapid changes taking place in the global operating environment facing the pharmaceutical industry. Through the establishment of the new roles of Chief Scientific Officer and Executive Vice President, International Operations, Takeda can better align its vision, strategies and goals for its R&D operations and its overseas commercial network. By doing so, the new structure enables Takeda to further realize itself as an R&D-driven pharmaceutical company, to consistently produce new drugs, and to realize the full potential of these products in the global market. Takeda has also established a Chief Administrative Officer role to provide a comprehensive vision and strategy for global administrative functions and to promote cooperation among the Human Resou
  • 17 X. Pipeline Development Activities ■ New compounds ■ Additional indications/new formulations ■ Characteristics of projects ■ Other alliance projects ■ Clinical study protocol summaries ■ Outcome studies Research Activities ■ Main joint research activities 18 Development activities ■ New Compounds Development code Drug Class (administration route) Indications Stage In-house/ In-license SYR-322 DPP-4 inhibitor (oral) Diabetes mellitus Diabetes mellitus (Fixed-dose combination with ACTOS) US Jpn EU US EU Filed (Dec 07) Filed (Sep 08) P-III Filed (Sep 08) P-III In-house TAK-390MR Proton pump inhibitor (oral) Erosive esophagitis (healing and maintenance) and non-erosive gastro-esophageal reflux disease US Jpn Filed (Dec 07) P-II In-house TAK-375 MT1/MT2 receptor agonist (oral) Insomnia Circadian rhythm sleep disorder (CRSD) EU Jpn US P-III *Re-submission of a MAA is under consideration Filed (Feb 08) P-II In-house Vectibix TM Fully
  • Third Quarter Financial Results for Fiscal 2008 Conference Call February 3, 2009 Takeda Pharmaceutical Company Limited FY2008 1-3Q Financial Results Nine months ended December 31, 2008 Hiroshi Takahara Corporate Officer, General Manager Finance & Accounting Department FY2007 FY2008 ( '07 / 4-12 ) ( '08 / 4-12 ) Billi f Billi f Billi f Year-on-year change Consolidated Financial Summary Billions of yen Billions of yen Billions of yen Net sales 1,076.0 1,202.8 + 126.8 + 11.8% Operating income 405.8 239.9 - 166.0 - 40.9% Ordinary income 506.2 254.6 - 251.6 - 49.7% Net income 331.4 168.6 - 162.8 - 49.1% R&D expenses 170.2 377.6 + 207.4 + 121.8% Including Inprocess R&D 163.5 + 163.5 EPS 362.64 yen 370.71 yen + 8.07 yen + 2.2% 2 * * excluding the effects of extraordinary profit/loss and other special factors Currency Translation Effect (Comparison with FY2007 4-12) (Unit: billions of yen) Total US$ Euro Others 1US$ 117yen 103yen 1Euro 163yen 151yen excluding Currency Translation Effect - 14 yen - 12 yen Net sales +
  • Establishing ag Global Pharmaceutical Company - Key Policies for FY2009 - Yasuchika Hasegawa President Takeda Pharmaceutical Company Limited Maintaining and expanding sales Key Policies for FY2009 in Japan, the US, Europe, and Asia Enhancing R&D structure to achieve steady launch of in-house products - Strategic shift from raw IND numbers and speed to overall project quality - 1 Establishing a structure to support global business operations and accelerate human resource development Maintaining and Expanding Sales in Japan, the US, Europe, and Asia 2 Maintaining Sales of TPNA Further growth of existing mainstay products Quickest possible penetration of new products into the market M i t i i k t h f ACTOSMaintaining market share of ACTOS family through aggressive promotion KAPIDEX: Aiming to switch from PREVACID and other brand drugs ULORIC: ($MM) 3 (E) Invigorating the market as the first new gout drug in the past 40 years Maintaining No.1 Position in Japan Further growth of existing ma
  • Takeda Pharmaceutical Company Limited (4502) Consolidated Financial Statements for Fiscal 2008 - 17 - 2. The Takeda Group Takeda Pharmaceutical Company Limited (4502) Consolidated Financial Statements for Fiscal 2008 - 18 - Consolidated Subsidiaries and Affiliates (Consolidated Subsidiaries) Company name Address Capital (millions of yen) Principal business Voting shares owned (%) Relationship Business transactions Other Nihon Pharmaceutical Co., Ltd. Chiyoda-ku, Tokyo, Japan 760 Pharmaceuticals (Ethical Drugs) 87.5 (0.2) Sells drugs, etc., to Takeda Takeda Pharmaceuticals North America, Inc. Deerfield, IL U.S.A. US$1 Pharmaceuticals (Ethical Drugs) 100.0* (100.0) Purchases drugs from Takeda Millennium Pharmaceuticals, Inc. Cambridge, MA U.S.A. US$0.1 Pharmaceuticals (Ethical Drugs) 100.0* (100.0) Handles drug research and development on behalf of Takeda and contract out to Takeda Takeda Pharmaceuticals Europe, Limited London, United Kingdom 4 million Pharmaceuticals (Ethical Drugs) 100.0** (100.0) Takeda Pha
  • Takeda Pharmaceutical Company Limited (4502) Consolidated Financial Statements for Fiscal 2008 - 20 - 3. Management Policy (1) Basic Management Policy Focusing on "Takeda-ism" (which refers to integrity = fairness, honesty, and perseverance) as the basis for all its business activities, Takeda is aiming at realizing its management mission of "striving toward better health for individuals and progress in medicine by developing superior pharmaceutical products" through creating new drugs continuously and maximizing the product's potential in the global market as a research-based pharmaceutical company. In order to realize Takeda's goal of establishing itself as a "global pharmaceutical company" as targeted in the 20062010 Medium-term Plan, Takeda created corporate-level, center of excellence R&D, commercial and administrative functions in fiscal 2009, and we will build its organization for global operations. Takeda will dedicate its collective efforts to thoroughly enhance its strengths, such as its "capabilit
  • Takeda Pharmaceutical Company Limited (4502) SUMMARY OF FINANCIAL STATEMENTS (Consolidated) Six Months Results (April 1 to September 30, 2008) - 13 - (8) Research & Development Seeking to enhance its R&D pipelines, which serve as sources for growth, and the earliest possible launch of new products into the market, Takeda intensively invests its management resources in its core therapeutic areas of lifestyle-related diseases; oncology and urological diseases (including gynecology); central nervous system diseases (including bone and joint disorders); and gastroenterological diseases, through the three strategic pillars of in-house research and development, maximization of product added value and in-licensing and alliances. Major results of R&D activities during the six months ended September 30, 2008 are: [In-house R&D] - In June 2008, at the 68th convention of the American Diabetes Association, the results of the Phase III clinical trials for alogliptin (a drug for Type II diabetes "SYR-322") were presented.
  • - 1 - SUMMARY OF FINANCIAL STATEMENTS (Consolidated) Six Months Results (April 1 to September 30, 2008) for the Fiscal Year Ending March 31, 2009 November 4, 2008 Takeda Pharmaceutical Company Limited Listed exchanges: Osaka, Tokyo, Nagoya, Fukuoka, Sapporo TSE Code: 4502 URL: http://www.takeda.co.jp Representative: Yasuchika Hasegawa, President Contact: Hirofumi Inoue, General Manager of Corporate Communications Department Telephone: +81 3 3278-2037 Scheduled date of securities report submission: November 14, 2008 Scheduled date of dividend payment commencement: December 1, 2008 1. Consolidated Financial Results (April 1 to September 30, 2008) for the Fiscal Year Ending March 31, 2009 (Millions of yen, rounded to the nearest million) (1) Consolidated Operating Results (aggregated) (Percentage figures represent changes from the same period of the previous year.) Net sales Operating income Ordinary income Net income ( million) change (%) ( million) change (%) ( million) change (%) ( million) change (%) Six mo
  • - 1 - SUMMARY OF FINANCIAL STATEMENTS (Consolidated) Six Months Results (April 1 to September 30, 2008) for the Fiscal Year Ending March 31, 2009 November 4, 2008 Takeda Pharmaceutical Company Limited Listed exchanges: Osaka, Tokyo, Nagoya, Fukuoka, Sapporo TSE Code: 4502 URL: http://www.takeda.co.jp Representative: Yasuchika Hasegawa, President Contact: Hirofumi Inoue, General Manager of Corporate Communications Department Telephone: +81 3 3278-2037 Scheduled date of securities report submission: November 14, 2008 Scheduled date of dividend payment commencement: December 1, 2008 1. Consolidated Financial Results (April 1 to September 30, 2008) for the Fiscal Year Ending March 31, 2009 (Millions of yen, rounded to the nearest million) (1) Consolidated Operating Results (aggregated) (Percentage figures represent changes from the same period of the previous year.) Net sales Operating income Ordinary income Net income ( million) change (%) ( million) change (%) ( million) change (%) ( million) change (%) Six mo
  • Takeda Pharmaceutical Company Limited (4502) SUMMARY OF FINANCIAL STATEMENTS (Consolidated) Six Months Results (April 1 to September 30, 2008) - 15 - 3. Descriptive Information on Forecasts of Consolidated Results The outlook for consolidated result for the full year of fiscal 2008 is as follows: Billions of yen Year-on-year change Net sales 1,560.0 Increase 185.2 (13.5%) Operating income 270.0 Decrease 153.1 (36.2%) Ordinary income 290.0 Decrease 246.4 (45.9%) Net income 195.0 Decrease 160.5 (45.1%) [Net sales] Despite unfavorable impact of strong yen, consolidated net sales are expected to increase from the previous year due to inclusion of TAP and Millennium into the consolidation, in addition to growth of sales of Actos, Takepron and Embrel (a drug for rheumatoid arthritis) in Japan. [Operating income] Although gross profit will increase from the previous year by sales growth, operating income will decrease due to R&D expenses and amortization of intangible assets in connection with the Millennium acquis
  • - 1 - SUMMARY OF FINANCIAL STATEMENTS (Consolidated) Six Months Results (April 1 to September 30, 2008) for the Fiscal Year Ending March 31, 2009 November 4, 2008 Takeda Pharmaceutical Company Limited Listed exchanges: Osaka, Tokyo, Nagoya, Fukuoka, Sapporo TSE Code: 4502 URL: http://www.takeda.co.jp Representative: Yasuchika Hasegawa, President Contact: Hirofumi Inoue, General Manager of Corporate Communications Department Telephone: +81 3 3278-2037 Scheduled date of securities report submission: November 14, 2008 Scheduled date of dividend payment commencement: December 1, 2008 1. Consolidated Financial Results (April 1 to September 30, 2008) for the Fiscal Year Ending March 31, 2009 (Millions of yen, rounded to the nearest million) (1) Consolidated Operating Results (aggregated) (Percentage figures represent changes from the same period of the previous year.) Net sales Operating income Ordinary income Net income ( million) change (%) ( million) change (%) ( million) change (%) ( million) change (%) Six mo
  • Takeda Pharmaceutical Company Limited (4502) SUMMARY OF FINANCIAL STATEMENTS (Consolidated) Six Months Results (April 1 to September 30, 2008) - 27 - For Reference Unconsolidated Financial Statements (Summary) (1) Unconsolidated Balance Sheets Millions of yen Account As of September 30, 2008 Amount As of March 31, 2008 (summary) Amount ASSETS Current assets Cash and deposits 155,032 108,760 Trade notes receivable 5,108 4,732 Trade accounts receivable 191,648 169,019 Marketable securities 236,258 479,097 Inventories 76,262 72,391 Deferred tax assets 131,117 117,136 Other current assets 22,511 28,364 Allowance for doubtful receivables (6) (6) Total current assets 817,932 979,493 Fixed assets Tangible fixed assets 103,587 104,257 Intangible fixed assets 4,863 81 Investments and other assets 727,681 747,872 Total fixed assets 836,131 852,210 Total assets 1,654,063 1,831,704 (Note) This unconsolidated balance sheet is not subject to review by auditors. Takeda Pharmaceutical Company Limited (4502) SUMMARY OF FINAN
  • Takeda Pharmaceutical Company Limited (4502) SUMMARY OF FINANCIAL STATEMENTS (Consolidated) Six Months Results (April 1 to September 30, 2008) - 15 - 3. Descriptive Information on Forecasts of Consolidated Results The outlook for consolidated result for the full year of fiscal 2008 is as follows: Billions of yen Year-on-year change Net sales 1,560.0 Increase 185.2 (13.5%) Operating income 270.0 Decrease 153.1 (36.2%) Ordinary income 290.0 Decrease 246.4 (45.9%) Net income 195.0 Decrease 160.5 (45.1%) [Net sales] Despite unfavorable impact of strong yen, consolidated net sales are expected to increase from the previous year due to inclusion of TAP and Millennium into the consolidation, in addition to growth of sales of Actos, Takepron and Embrel (a drug for rheumatoid arthritis) in Japan. [Operating income] Although gross profit will increase from the previous year by sales growth, operating income will decrease due to R&D expenses and amortization of intangible assets in connection with the Millennium acquis
  • Takeda Pharmaceutical Company Limited (4502) SUMMARY OF FINANCIAL STATEMENTS (Consolidated) Six Months Results (April 1 to September 30, 2008) - 17 - 5. Six-Month Consolidated Financial Statements (April 1 to September 30, 2008) (1) Consolidated Balance Sheets Millions of yen Account As of September 30, 2008 Amount As of March 31, 2008 (summary) Amount ASSETS Current assets Cash and deposits 301,480 239,528 Notes and accounts receivable 339,118 248,189 Marketable securities 497,198 1,445,465 Merchandise 19,354 16,892 Products 36,718 36,540 Semi-finished products 37,167 31,074 Raw materials 31,534 29,718 Work in process 2,732 1,908 Deferred tax assets 201,453 140,962 Other 82,221 54,415 Allowance for doubtful receivables (940) (899) Total current assets 1,548,035 2,243,792 Fixed assets Tangible fixed assets 253,894 236,134 Intangible fixed assets Goodwill 315,639 3,656 Patents 518,065 Other 9,403 6,535 Total intangible fixed assets 843,107 10,191 Investments and other assets Investment securities 260,138 292,
  • Takeda Pharmaceutical Company Limited (4502) SUMMARY OF FINANCIAL STATEMENTS (Consolidated) Six Months Results (April 1 to September 30, 2008) - 15 - 3. Descriptive Information on Forecasts of Consolidated Results The outlook for consolidated result for the full year of fiscal 2008 is as follows: Billions of yen Year-on-year change Net sales 1,560.0 Increase 185.2 (13.5%) Operating income 270.0 Decrease 153.1 (36.2%) Ordinary income 290.0 Decrease 246.4 (45.9%) Net income 195.0 Decrease 160.5 (45.1%) [Net sales] Despite unfavorable impact of strong yen, consolidated net sales are expected to increase from the previous year due to inclusion of TAP and Millennium into the consolidation, in addition to growth of sales of Actos, Takepron and Embrel (a drug for rheumatoid arthritis) in Japan. [Operating income] Although gross profit will increase from the previous year by sales growth, operating income will decrease due to R&D expenses and amortization of intangible assets in connection with the Millennium acquis
  • On the intranet website, Philan-net Takeda (PINT), information on regional volunteer activities is transmitted for employees. "Climbing Mt. Tenno for cleaning," a voluntary project by PINT Osaka is one such example, featuring contributions to society through the activity of cleaning a mountain climbing route, using handmade bamboo tongs to grab garbage, in a step-by-step fashion. PINT also provides a variety of information on Takeda's social action programs and the introduction of NPOs, aiming to play a role as a medium to bridge social needs and the employees' aspirations toward society. The area directly related to the Mission: "we strive toward better health for individuals and progress in medicine by developing superior pharmaceutical products" The area concerning "the aim to live an affluent life with body and mind in good health," as well as "eliminating any obstacles to such a goal" based on the Mission Contributions toward developing a bright and dream-inspiring future The projects to be inherited an
  • 1 Takeda Pharmaceutical Company Limited First Quarter Financial ResultsFirst Quarter Financial Results for Fiscal 2007for Fiscal 2007 Conference Call July 31, 2007Conference Call July 31, 2007 Takeda Pharmaceutical Company Limited Takeda Pharmaceutical Company Limited Takeda Pharmaceutical Company Limited Consolidated ResultsConsolidated Results First Quarter of Fiscal 2007First Quarter of Fiscal 2007 Hiroshi Takahara Corporate Officer, General Manager Finance & Accounting Department Takeda Pharmaceutical Company Limited 2 3 Takeda Pharmaceutical Company Limited Outline of Consolidated ResultsOutline of Consolidated Results '06 1Q '07 1Q Year-on-year change billions of yen billions of yen billions of yen <%> Net sales 334.3 366.3 32.0 < 9.6 > Operating income 132.1 153.1 21.0 < 15.9 > Ordinary income 162.6 190.4 27.9 < 17.2 > (Extraordinary income) 【38.2 】 【29.1 】 【- 9.1 】 < - 23.8 > Net income 124.6 131.0 6.4 < 5.1 > R&D expenses 50.6 47.3 - 3.3 < - 6.5 > E P S 141.30 yen 152.74 yen 11.44 yen < 8.1 >
  • Takeda Pharmaceutical Company Limited Summary of Consolidated Results for 1H FY06 and Projection for FY06 Hiroshi Takahara Corporate Officer General Manager, Finance & Accounting Dept. 2 Takeda Pharmaceutical Company Limited Performance Summary 1st half FY06 1H FY05 1H FY06 Change bln yen bln yen in bln yen / in percent Net sales 599.8 642.4 +42.6 +7.1% Operating income 215.2 236.2 +21.0 +9.7% Ordinary income 259.4 299.0 +39.6 +15.3% 【Extraordinary gain】 【32.6】 【38.3】 【+5.7】 +17.6% Net income 181.3 159.1 -22.1 -12.2% R&D expenses 82.3 96.2 +13.9 +16.9% EPS 204.8 yen 181.3 yen -23.5 -11.5% ROE 17.2 % 13.6 % -3.6 3 Takeda Pharmaceutical Company Limited Performance Summary 1st half FY06 1st half FY06 Est. Actual Change bln yen as of '06/5 in bln yen / in percent Net sales 605.0 642.4 +37.4 +6.2% Operating income 195.0 236.2 +41.2 +21.1% Ordinary income 245.0 299.0 +54.0 +22.1% Net income 175.0 159.1 -15.9 -9.1% R&D expenses 95.0 96.2 +1.2 +1.2% EPS 197.7 181.3 yen -16.4 -8.3% 4 Takeda Pharmaceutical Com

Pages:[1] [2] [3] [4] [5] [6] [7] [8] [9] [10]   Next

Page Top